Tag: VIVA

Vascular Specialist–October 2021

In this issue: "Not all cuts disappear": We take a look at the threat posed to vascular surgery—and the office-based lab (OBL) setting in...

PROMISE I 24-month results ‘validate the benefits of the LimFlow system’

LimFlow has announced 24-month results from the PROMISE I study of the LimFlow percutaneous deep vein arterialization system, confirming “excellent and sustained outcomes” for...

IN.PACT AV DCB sustained ‘superior’ effectiveness in subgroups with high reintervention...

Several subgroups of patients treated with the IN.PACT AV drug-coated balloon (DCB) for arteriovenous fistulas (AVFs) demonstrated a “statistically significant” higher rate of target...

Two-year Ranger DCB data demonstrate ‘sustained, high rate’ of device efficacy

Patients treated with Boston Scientific’s Ranger drug-coated balloon (DCB) sustained “improved primary patency” with fewer reinterventions than those treated with uncoated devices, two-year results...

VIVA 2021: IN.PACT Admiral DCB found to provide ‘high five-year freedom...

Real-world data drawn from the IN.PACT Global study looking at five-year freedom from clinically driven target lesion revascularization (TLR) among prespecified chronic total occlusion...

Intravascular lithotripsy ‘superior’ to PTA in acute procedural success out to...

The DISRUPT PAD III randomized controlled trial (RCT) provides the largest level-one evidence for the treatment of heavily calcified femoropopliteal arteries, noted William Gray,...

Latest VOYAGER PAD analysis finds no mortality and improved limb outcomes...

Given the absence of a safety signal in data from the VOYAGER PAD trial, a new analysis examined the potential benefit of drug-coated device...

Medical education requires a reboot in the digital age, argues stent-grafting...

LAS VEGAS—Medical education is confronted by huge opportunities with the coming of what has been termed the fourth industrial revolution—that of the intersection where...